In this work, we emphasize a well-known cancerous genomic alteration: the amplification of MYCN and its downstream effects in neuroblastoma phenotype evolution.

Jul 9, 2024 · A phase 1/2 clinical trial is testing an investigational drug called PLX038 on hard-to-treat central nervous system tumors containing extra copies of the MYC and MYCN genes. Nearly 100,000 new cases of primary brain and spine tumors …

Dec 12, 2015 · We employed a multi-level omics approach to examine MYCN functioning and identify novel therapeutic targets for this largely un-druggable oncogene.

Amplification of the MYCN oncogene, a member of the MYC family of transcriptional regulators, is one of the most powerful prognostic markers identified for poor outcome in neuroblastoma, the most common extracranial solid cancer in childhood.

Nov 29, 2021 · Here we show that MYCN interacts with and recruits the nuclear exosome to its target genes and that MYCN-amplified neuroblastoma cells depend on the exosome to maintain productive elongation and prevent excessive DNA damage.

Dec 1, 2024 · The fact, that MYCN-amplified neuroblastoma cells exhibit high expression levels of PARP1 and PARP2 made them potential cancer therapeutic targets. MYCN expression led to cell death upon treatment with various PARP inhibitors, …

Among patients with low-stage, MYCN -amplified neuroblastoma, outcomes of patients with hyperdiploid tumors were statistically, significantly better than those with diploid tumors. The data suggest that tumor cell ploidy could potentially be used to …

Mar 15, 2024 · In a new study from Boston University Chobanian & Avedisian School of Medicine, researchers found that MYCN selectively increases the levels of a signaling molecule, CKLF, in neuroblastoma cells...

Jul 18, 2009 · Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN -amplification does not automatically result in higher expression of MYCN in children with NB.

Jan 15, 2013 · Amplification of MYCN oncogene is an established marker indicating aggressive tumor progression of neuroblastoma (NBL). But copy number analyses of MYCN gene in ganglioneuroblastoma (GNBL) and ganglioneuroma(GN) is poorly described in the literature.